General
PCSK9 Inhibitors and the Choice Between Innovation, Efficiency, and Affordability
 

PCSK9 Inhibitors and the Choice Between Innovation, Efficiency, and Affordability

Shared by:

 
Cardiovascular medicine is struggling with the new proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor drugs for lowering low-density lipoprotein cholesterol (LDL), not primarily because of efficacy concerns or safety issues, but because the price of these new agents exceeds $14 000 a...
 
jamanetwork.com
 
3 Sep 2017 - General
 
Thank you Shunjie Chua for sharing this update on the management of elevated LDL levels. Elevated LDL has been linked with an increased risk of cardiovascular diseases and myocardial infarction. The PCSK9 inhibitor showed good efficacy and safety in terms of reducing LDL levels; however, its cost effectiveness is put in question as it costs 14,000 USD per year for the patient. I hope there is a resolution that ...
 (Total 80 words)